Please ensure Javascript is enabled for purposes of website accessibility

Why Ocugen Stock Couldn't Outrun the Market Today

By Eric Volkman – Jan 12, 2022 at 12:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The coronavirus vaccine that it has licensed does very well against variants like omicron, but it's still a laggard.

What happened

Like the broader stock market, Ocugen (OCGN 3.59%) shares ticked up well shy of 1% on Wednesday. The biotech had some good news to report about the coronavirus vaccine that it's licensing, but this didn't move the needle much for investors.

So what

This morning, Ocugen happily announced that the vaccine Covaxin did well in a clinical study conducted at Emory University in Georgia. The findings indicate that a Covaxin booster, given to people who had previously undergone the standard two-dose regime of the vaccine, neutralized the delta and omicron variants of the coronavirus. It did the same against variants of concern alpha, beta, zeta, and kappa.

Gloved hand filling a syringe from a vial.

Image source: Getty Images.

Ocugen said that more than 90% of the study's subjects showed neutralizing antibodies.

"These results show how a broad-spectrum vaccine has the potential ability to address ever-shifting public health challenges such as new variants and mutations," CEO Shankar Musunuri was quoted as saying.

Covaxin is being developed by India's Bharat Biotech; Ocugen holds the North American commercial rights to the vaccine. It's currently under review by the Food and Drug Administration for Emergency Use Authorization, and as such it is not one of the three vaccines currently approved or authorized by the American regulator.

Now what

While the new study bolsters Covaxin's status as an efficacious weapon in the fight against the coronavirus, Ocugen is still rather behind the pack in the vaccine race.

Other jabs have taken what seems to be a permanent lead -- most notably Comirnaty from pharmaceutical giant Pfizer and its partner BioNTech -- and that's not likely to change no matter how many variants are blocked by Covaxin. 

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.